Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18282736 | 0.88 | PDE2A (1.00) | PDE2ARET | |
| SCHEMBL20581431 | 0.88 | PDE2A (0.74) | PDE2AALDH1A1RETGHSRXIAP | |
| SCHEMBL20138405 | 0.87 | PDE2A (0.79) | PDE2AGPR139 | |
| SCHEMBL18283117 | 0.86 | PDE2A (0.69) | PDE2AALDH1A1RETGHSRXIAP | |
| SCHEMBL20202566 | 0.86 | PDE2A (0.60) | PDE2ATP53ALDH1A1LMNANPSR1 | |
| SCHEMBL24211353 | 0.83 | PDE2A (0.65) | PDE2ARETGHSRXIAP | |
| SCHEMBL18282926 | 0.83 | PDE2A (0.76) | PDE2ARETGHSR | |
| SCHEMBL20138449 | 0.82 | PDE2A (0.67) | PDE2ALMNARETGPR139GHSR | |
| SCHEMBL20138441 | 0.82 | PDE2A (0.69) | PDE2AALDH1A1LMNANPSR1RET | |
| SCHEMBL20138450 | 0.81 | PDE2A (0.71) | PDE2ALMNARETGHSRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | PDE2A 2/4885TP53 4186/4885ALDH1A1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.